FDA Adds KRAS Testing Info to Vectibix, Erbitux Labels | GenomeWeb

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has revised the prescribing information for a class of epidermal growth factor receptor inhibitors for colorectal cancer to include information on variations in the KRAS gene that may affect patient response to the drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.